JP2020513769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513769A5 JP2020513769A5 JP2019536073A JP2019536073A JP2020513769A5 JP 2020513769 A5 JP2020513769 A5 JP 2020513769A5 JP 2019536073 A JP2019536073 A JP 2019536073A JP 2019536073 A JP2019536073 A JP 2019536073A JP 2020513769 A5 JP2020513769 A5 JP 2020513769A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antigen
- antibody
- binding fragment
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 201000001981 dermatomyositis Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 12
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims description 7
- 208000026278 immune system disease Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010003230 arteritis Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 210000004969 inflammatory cell Anatomy 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 208000005987 polymyositis Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 206010043207 temporal arteritis Diseases 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 210000000441 neoplastic stem cell Anatomy 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000002829 CREST Syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101800004637 Communis Proteins 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 108010091326 Cryoglobulins Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000021908 Myocardial disease Diseases 0.000 claims description 2
- 241000244206 Nematoda Species 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038111 Recurrent cancer Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims description 2
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims description 2
- 229950010333 exalamide Drugs 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000009390 immune abnormality Effects 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 230000000366 juvenile effect Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 2
- 230000000552 rheumatic effect Effects 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762441551P | 2017-01-02 | 2017-01-02 | |
| US62/441,551 | 2017-01-02 | ||
| US201762445673P | 2017-01-12 | 2017-01-12 | |
| US62/445,673 | 2017-01-12 | ||
| PCT/US2018/012040 WO2018126259A1 (en) | 2017-01-02 | 2018-01-02 | Anti-lair1 antibodies and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513769A JP2020513769A (ja) | 2020-05-21 |
| JP2020513769A5 true JP2020513769A5 (enExample) | 2021-02-12 |
| JP7152404B2 JP7152404B2 (ja) | 2022-10-12 |
Family
ID=62710796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536073A Active JP7152404B2 (ja) | 2017-01-02 | 2018-01-02 | 抗ｌａｉｒ１抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11377491B2 (enExample) |
| EP (1) | EP3562508A4 (enExample) |
| JP (1) | JP7152404B2 (enExample) |
| KR (1) | KR102617853B1 (enExample) |
| CN (1) | CN110381998B (enExample) |
| AU (1) | AU2018204986B2 (enExample) |
| CA (1) | CA3047593A1 (enExample) |
| WO (1) | WO2018126259A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020014387A1 (en) * | 2018-07-10 | 2020-01-16 | Akamara Therapeutics, Inc. | B-cell immunotherapy in cancer treatment |
| EP4076526A4 (en) | 2019-12-17 | 2024-07-03 | The Board Of Regents Of The University Of Texas System | Novel ddr1 antibodies and uses thereof |
| US12240899B2 (en) * | 2020-06-22 | 2025-03-04 | Ngm Biopharmaceuticals, Inc. | LAIR-1-binding agents and methods of use thereof |
| US20240117072A1 (en) * | 2020-12-18 | 2024-04-11 | Bioardis, Llc | Fap binding molecules and uses thereof |
| WO2022177995A1 (en) * | 2021-02-17 | 2022-08-25 | University Of Florida Research Foundation, Incorporated | Anti-lair1 antibodies for the treatment of cancer |
| WO2023173091A1 (en) | 2022-03-11 | 2023-09-14 | Ngm Biopharmaceuticals, Inc. | Osteoclast-associated ig-like receptor (oscar) and methods of use thereof |
| AR130506A1 (es) * | 2022-09-16 | 2024-12-11 | Lilly Co Eli | Anticuerpos anti-lair1 humano |
| WO2024067864A1 (en) * | 2022-09-30 | 2024-04-04 | Shanghai Junshi Biosciences Co., Ltd. | Anti-lair1 antibodies and their uses |
| TW202444761A (zh) * | 2023-04-11 | 2024-11-16 | 美商恩格姆生物製藥公司 | 使用ｌａｉｒ１結合劑治療骨肉瘤之方法 |
| WO2024215787A1 (en) * | 2023-04-11 | 2024-10-17 | Ngm Biopharmaceuticals, Inc. | Methods of treating osteosarcoma using lair1 binding agents and pd-1 antagonists |
| CN120230216B (zh) * | 2025-05-29 | 2025-09-09 | 上海宏成药业有限公司 | 抗lair1抗体及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007102736A2 (en) | 2006-03-08 | 2007-09-13 | Universitair Medisch Centrum Utrecht | Interfering in activation of an immune cell by influencing interaction of lair and collagen. |
| WO2010007858A1 (ja) * | 2008-07-15 | 2010-01-21 | 株式会社村田製作所 | 電子部品 |
| WO2010078580A2 (en) * | 2009-01-05 | 2010-07-08 | The Johns Hopkins University | Immunotherapy for contact dermatitis using co-signal regulation |
| US12128069B2 (en) * | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
-
2018
- 2018-01-02 CN CN201880015331.9A patent/CN110381998B/zh active Active
- 2018-01-02 EP EP18734005.4A patent/EP3562508A4/en active Pending
- 2018-01-02 JP JP2019536073A patent/JP7152404B2/ja active Active
- 2018-01-02 WO PCT/US2018/012040 patent/WO2018126259A1/en not_active Ceased
- 2018-01-02 US US16/475,223 patent/US11377491B2/en active Active
- 2018-01-02 KR KR1020197022485A patent/KR102617853B1/ko active Active
- 2018-01-02 AU AU2018204986A patent/AU2018204986B2/en active Active
- 2018-01-02 CA CA3047593A patent/CA3047593A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513769A5 (enExample) | ||
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| US11760795B2 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer | |
| CN103068851B (zh) | 内质蛋白的抗体及其用途 | |
| JP2020510422A5 (enExample) | ||
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| JP2019509976A5 (enExample) | ||
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| CN107922938B (zh) | 抗体 | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| WO2024001669A1 (zh) | 靶向itga2的抗体和包含此抗体的抗体药物缀合物 | |
| US8974786B2 (en) | Humanized antibodies to CA215 | |
| JP7059388B2 (ja) | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| TW202400662A (zh) | 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途 | |
| WO2023222135A1 (en) | A method of treating solid tumor | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| WO2024245388A1 (zh) | 抗pvrig抗体及其应用 | |
| KR20250069411A (ko) | 항 ceacam5 항체 및 이의 용도 | |
| CA2943694C (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
| CA3254238A1 (en) | METHOD AND APPARATUS FOR DETERMINING THE OPERATING PARAMETERS OF A WIRELESS ROUTER | |
| RU2020108444A (ru) | Биспецифические антитела и способы их получения и применения | |
| HK1231096B (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
| HK1231096A1 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
| JPWO2022103660A5 (enExample) |